CA2539230A1 - Combinaisons d'un inhibiteur du recepteur du vegf et d'autres agents therapeutiques - Google Patents

Combinaisons d'un inhibiteur du recepteur du vegf et d'autres agents therapeutiques Download PDF

Info

Publication number: CA2539230A1
Authority: CA; Canada
Prior art keywords: mono; lower alkyl; group; independently; phenyl
Prior art date: 2003-09-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002539230A

Other languages

English (en)

Inventor

Guido Bold

Josef Bernhard Brueggen

Jerry Min-Jian Huang

Frederick Ray Kinder, Jr.

Heidi Lane

Elisabeth Jeanne Latour

Paul William Manley

Jeanette Marjorie Wood

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-23

Filing date

2004-09-23

Publication date

2005-03-31

2004-09-23 Application filed by Individual filed Critical Individual

2005-03-31 Publication of CA2539230A1 publication Critical patent/CA2539230A1/fr

Status Abandoned legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims abstract description 30
229940124597 therapeutic agent Drugs 0.000 title claims abstract description 26
239000003112 inhibitor Substances 0.000 title claims abstract description 18
108091008605 VEGF receptors Proteins 0.000 title description 6
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims abstract description 89
239000002525 vasculotropin inhibitor Substances 0.000 claims abstract description 41
201000010099 disease Diseases 0.000 claims abstract description 26
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
239000005557 antagonist Substances 0.000 claims abstract description 9
108090000102 pigment epithelium-derived factor Proteins 0.000 claims abstract description 9
208000022873 Ocular disease Diseases 0.000 claims abstract description 8
208000017169 kidney disease Diseases 0.000 claims abstract description 8
239000003504 photosensitizing agent Substances 0.000 claims abstract description 8
230000004663 cell proliferation Effects 0.000 claims abstract description 7
208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
230000008595 infiltration Effects 0.000 claims abstract description 7
238000001764 infiltration Methods 0.000 claims abstract description 7
210000004969 inflammatory cell Anatomy 0.000 claims abstract description 7
208000011514 Familial renal glucosuria Diseases 0.000 claims abstract description 6
206010020772 Hypertension Diseases 0.000 claims abstract description 6
229940121856 Somatostatin receptor antagonist Drugs 0.000 claims abstract description 6
230000000964 angiostatic effect Effects 0.000 claims abstract description 6
239000003246 corticosteroid Substances 0.000 claims abstract description 6
229960001334 corticosteroids Drugs 0.000 claims abstract description 6
239000007943 implant Substances 0.000 claims abstract description 6
102000006495 integrins Human genes 0.000 claims abstract description 6
108010044426 integrins Proteins 0.000 claims abstract description 6
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract description 6
239000002599 prostaglandin synthase inhibitor Substances 0.000 claims abstract description 6
208000007278 renal glycosuria Diseases 0.000 claims abstract description 6
150000003431 steroids Chemical class 0.000 claims abstract description 6
239000005541 ACE inhibitor Substances 0.000 claims abstract description 5
239000002333 angiotensin II receptor antagonist Substances 0.000 claims abstract description 5
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 5
229940043355 kinase inhibitor Drugs 0.000 claims abstract description 5
239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 5
102000009929 raf Kinases Human genes 0.000 claims abstract description 5
108010077182 raf Kinases Proteins 0.000 claims abstract description 5
102100035846 Pigment epithelium-derived factor Human genes 0.000 claims abstract 3
-1 2,1,3-benzothiadiazol-4-yl Chemical group 0.000 claims description 205
125000000217 alkyl group Chemical group 0.000 claims description 109
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 52
150000003839 salts Chemical class 0.000 claims description 52
125000001424 substituent group Chemical group 0.000 claims description 49
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
229910052736 halogen Inorganic materials 0.000 claims description 34
125000003118 aryl group Chemical group 0.000 claims description 33
150000002367 halogens Chemical class 0.000 claims description 32
125000001589 carboacyl group Chemical group 0.000 claims description 31
125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 27
239000001257 hydrogen Substances 0.000 claims description 27
125000004432 carbon atom Chemical group C* 0.000 claims description 26
229910052757 nitrogen Inorganic materials 0.000 claims description 26
229910052760 oxygen Inorganic materials 0.000 claims description 26
229910052717 sulfur Inorganic materials 0.000 claims description 26
125000001072 heteroaryl group Chemical group 0.000 claims description 24
239000008194 pharmaceutical composition Substances 0.000 claims description 21
125000004414 alkyl thio group Chemical group 0.000 claims description 20
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
125000002619 bicyclic group Chemical group 0.000 claims description 19
125000002950 monocyclic group Chemical group 0.000 claims description 19
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
150000001204 N-oxides Chemical class 0.000 claims description 18
125000005842 heteroatom Chemical group 0.000 claims description 18
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
238000000034 method Methods 0.000 claims description 16
239000001301 oxygen Substances 0.000 claims description 16
239000011593 sulfur Substances 0.000 claims description 16
125000002947 alkylene group Chemical group 0.000 claims description 15
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 14
125000000547 substituted alkyl group Chemical group 0.000 claims description 14
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 13
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
125000004076 pyridyl group Chemical group 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 12
125000004423 acyloxy group Chemical group 0.000 claims description 11
125000001841 imino group Chemical group [H]N=* 0.000 claims description 10
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 10
241000534944 Thia Species 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 6
206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 6
208000001344 Macular Edema Diseases 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 6
125000002252 acyl group Chemical group 0.000 claims description 6
229960005167 everolimus Drugs 0.000 claims description 6
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims description 6
125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 6
230000001772 anti-angiogenic effect Effects 0.000 claims description 5
229960004530 benazepril Drugs 0.000 claims description 5
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 5
229960003957 dexamethasone Drugs 0.000 claims description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
229960000994 lumiracoxib Drugs 0.000 claims description 5
125000003107 substituted aryl group Chemical group 0.000 claims description 5
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 4
206010003210 Arteriosclerosis Diseases 0.000 claims description 4
208000005590 Choroidal Neovascularization Diseases 0.000 claims description 4
206010060823 Choroidal neovascularisation Diseases 0.000 claims description 4
206010058202 Cystoid macular oedema Diseases 0.000 claims description 4
206010012688 Diabetic retinal oedema Diseases 0.000 claims description 4
108010016076 Octreotide Proteins 0.000 claims description 4
206010052779 Transplant rejections Diseases 0.000 claims description 4
206010064930 age-related macular degeneration Diseases 0.000 claims description 4
229960001232 anecortave Drugs 0.000 claims description 4
208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
229960000590 celecoxib Drugs 0.000 claims description 4
201000010206 cystoid macular edema Diseases 0.000 claims description 4
201000011190 diabetic macular edema Diseases 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
208000002780 macular degeneration Diseases 0.000 claims description 4
229960002700 octreotide Drugs 0.000 claims description 4
108700017947 pasireotide Proteins 0.000 claims description 4
229960005415 pasireotide Drugs 0.000 claims description 4
NEEFMPSSNFRRNC-HQUONIRXSA-N pasireotide aspartate Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 NEEFMPSSNFRRNC-HQUONIRXSA-N 0.000 claims description 4
201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 4
229960005294 triamcinolone Drugs 0.000 claims description 4
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 4
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 3
229940043075 fluocinolone Drugs 0.000 claims description 3
229960000371 rofecoxib Drugs 0.000 claims description 3
229960004699 valsartan Drugs 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
208000003120 Angiofibroma Diseases 0.000 claims description 2
206010006458 Bronchitis chronic Diseases 0.000 claims description 2
206010063209 Chronic allograft nephropathy Diseases 0.000 claims description 2
206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010012442 Dermatitis contact Diseases 0.000 claims description 2
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
201000009273 Endometriosis Diseases 0.000 claims description 2
206010016654 Fibrosis Diseases 0.000 claims description 2
208000010412 Glaucoma Diseases 0.000 claims description 2
206010018364 Glomerulonephritis Diseases 0.000 claims description 2
201000002563 Histoplasmosis Diseases 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
206010065630 Iris neovascularisation Diseases 0.000 claims description 2
206010025415 Macular oedema Diseases 0.000 claims description 2
206010029113 Neovascularisation Diseases 0.000 claims description 2
206010073286 Pathologic myopia Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
208000007135 Retinal Neovascularization Diseases 0.000 claims description 2
208000017442 Retinal disease Diseases 0.000 claims description 2
206010038923 Retinopathy Diseases 0.000 claims description 2
206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
208000027418 Wounds and injury Diseases 0.000 claims description 2
206010003246 arthritis Diseases 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
206010006451 bronchitis Diseases 0.000 claims description 2
208000007451 chronic bronchitis Diseases 0.000 claims description 2
230000007882 cirrhosis Effects 0.000 claims description 2
208000019425 cirrhosis of liver Diseases 0.000 claims description 2
208000010247 contact dermatitis Diseases 0.000 claims description 2
201000000159 corneal neovascularization Diseases 0.000 claims description 2
230000006378 damage Effects 0.000 claims description 2
208000033679 diabetic kidney disease Diseases 0.000 claims description 2
230000003176 fibrotic effect Effects 0.000 claims description 2
201000011066 hemangioma Diseases 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
208000014674 injury Diseases 0.000 claims description 2
230000000302 ischemic effect Effects 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
201000010230 macular retinal edema Diseases 0.000 claims description 2
230000003211 malignant effect Effects 0.000 claims description 2
201000003142 neovascular glaucoma Diseases 0.000 claims description 2
201000009925 nephrosclerosis Diseases 0.000 claims description 2
210000000944 nerve tissue Anatomy 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
230000001732 thrombotic effect Effects 0.000 claims description 2
238000002054 transplantation Methods 0.000 claims description 2
210000003462 vein Anatomy 0.000 claims description 2
230000029663 wound healing Effects 0.000 claims description 2
YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 claims 2
239000012828 PI3K inhibitor Substances 0.000 claims 2
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 2
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 1
238000002648 combination therapy Methods 0.000 abstract description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 71
125000003282 alkyl amino group Chemical group 0.000 description 40
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 31
125000004453 alkoxycarbonyl group Chemical group 0.000 description 29
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 28
150000003254 radicals Chemical class 0.000 description 27
125000003545 alkoxy group Chemical group 0.000 description 16
125000004390 alkyl sulfonyl group Chemical group 0.000 description 15
239000002253 acid Substances 0.000 description 14
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 13
229910052731 fluorine Inorganic materials 0.000 description 13
239000011737 fluorine Substances 0.000 description 13
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
239000000203 mixture Substances 0.000 description 12
239000004480 active ingredient Substances 0.000 description 11
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 10
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 10
229910052794 bromium Inorganic materials 0.000 description 10
229910052801 chlorine Inorganic materials 0.000 description 10
239000000460 chlorine Substances 0.000 description 10
125000000623 heterocyclic group Chemical group 0.000 description 10
229960003966 nicotinamide Drugs 0.000 description 10
239000011570 nicotinamide Substances 0.000 description 10
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 9
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
125000005236 alkanoylamino group Chemical group 0.000 description 8
125000005530 alkylenedioxy group Chemical group 0.000 description 8
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 8
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 6
125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 6
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 6
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 6
125000006610 n-decyloxy group Chemical group 0.000 description 6
125000001624 naphthyl group Chemical group 0.000 description 6
238000002428 photodynamic therapy Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
BYIWDFGWEKABGO-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1C1=CC=CC(C(F)(F)F)=C1 BYIWDFGWEKABGO-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
UIOAQJNADLELPQ-UHFFFAOYSA-N C[C]1OCCO1 Chemical group C[C]1OCCO1 UIOAQJNADLELPQ-UHFFFAOYSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
125000003342 alkenyl group Chemical group 0.000 description 4
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
125000001041 indolyl group Chemical group 0.000 description 4
238000001802 infusion Methods 0.000 description 4
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 4
BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 4
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 4
125000000168 pyrrolyl group Chemical group 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
108090000315 Protein Kinase C Proteins 0.000 description 3
102000003923 Protein Kinase C Human genes 0.000 description 3
SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 3
125000004466 alkoxycarbonylamino group Chemical group 0.000 description 3
125000004448 alkyl carbonyl group Chemical group 0.000 description 3
125000000304 alkynyl group Chemical group 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
125000006598 aminocarbonylamino group Chemical group 0.000 description 3
125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 3
150000004032 porphyrins Chemical class 0.000 description 3
239000000047 product Substances 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
125000005493 quinolyl group Chemical group 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 3
125000003831 tetrazolyl group Chemical group 0.000 description 3
125000000335 thiazolyl group Chemical group 0.000 description 3
125000001425 triazolyl group Chemical group 0.000 description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 2
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
XIKIWJNIFDAXKQ-UHFFFAOYSA-N 2-isoquinolin-3-ylpyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1C1=CC2=CC=CC=C2C=N1 XIKIWJNIFDAXKQ-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 2
125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
BCFCRXOJOFDUMZ-ONKRVSLGSA-N Anecortave Chemical compound O=C1CC[C@]2(C)C3=CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 BCFCRXOJOFDUMZ-ONKRVSLGSA-N 0.000 description 2
102000012936 Angiostatins Human genes 0.000 description 2
108010079709 Angiostatins Proteins 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
102400001047 Endostatin Human genes 0.000 description 2
108010079505 Endostatins Proteins 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000001361 adipic acid Substances 0.000 description 2
235000011037 adipic acid Nutrition 0.000 description 2
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229960004909 aminosalicylic acid Drugs 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
229940092714 benzenesulfonic acid Drugs 0.000 description 2
125000005605 benzo group Chemical group 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000036765 blood level Effects 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
235000013985 cinnamic acid Nutrition 0.000 description 2
229930016911 cinnamic acid Natural products 0.000 description 2
HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
SIVVHUQWDOGLJN-UHFFFAOYSA-N ethylsulfamic acid Chemical group CCNS(O)(=O)=O SIVVHUQWDOGLJN-UHFFFAOYSA-N 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
125000003838 furazanyl group Chemical group 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
239000003978 infusion fluid Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000005956 isoquinolyl group Chemical group 0.000 description 2
125000001786 isothiazolyl group Chemical group 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000001630 malic acid Substances 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 2
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
HLIBNTOXKQCYMV-UHFFFAOYSA-N propylsulfamic acid Chemical compound CCCNS(O)(=O)=O HLIBNTOXKQCYMV-UHFFFAOYSA-N 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000002098 pyridazinyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
229960002930 sirolimus Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 2
125000000542 sulfonic acid group Chemical group 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 2
229950000578 vatalanib Drugs 0.000 description 2
YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
QUPUZGXQWZELQK-UHFFFAOYSA-N 2-(1h-indazol-5-yl)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1C1=CC=C(NN=C2)C2=C1 QUPUZGXQWZELQK-UHFFFAOYSA-N 0.000 description 1
RGCPXQJMJGAUFW-UHFFFAOYSA-N 2-(2-pyridin-4-ylethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCCC=2C=CN=CC=2)=C1 RGCPXQJMJGAUFW-UHFFFAOYSA-N 0.000 description 1
BDRZBBQRTSXKOK-UHFFFAOYSA-N 2-(3-tert-butylphenyl)benzamide Chemical compound CC(C)(C)C1=CC=CC(C=2C(=CC=CC=2)C(N)=O)=C1 BDRZBBQRTSXKOK-UHFFFAOYSA-N 0.000 description 1
KOZYVFHWBZNWCW-UHFFFAOYSA-N 2-(7-hydroxynaphthalen-1-yl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC2=CC=C(O)C=C12 KOZYVFHWBZNWCW-UHFFFAOYSA-N 0.000 description 1
ODIUWSGXFVVAKM-UHFFFAOYSA-N 2-(benzylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CC=CC=2)=C1 ODIUWSGXFVVAKM-UHFFFAOYSA-N 0.000 description 1
AGXLCLDFWYKYHB-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-(1,3-thiazol-5-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC1=CN=CS1 AGXLCLDFWYKYHB-UHFFFAOYSA-N 0.000 description 1
HADXUECKLJSDLK-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-(5,6,7,8-tetrahydronaphthalen-1-yl)benzamide Chemical compound C=1C=CC=2CCCCC=2C=1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 HADXUECKLJSDLK-UHFFFAOYSA-N 0.000 description 1
BLAFVGLBBOPRLP-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 BLAFVGLBBOPRLP-UHFFFAOYSA-N 0.000 description 1
DTGXNZDPFAXKMU-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 DTGXNZDPFAXKMU-UHFFFAOYSA-N 0.000 description 1
HQODPNFXSQZUPQ-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 HQODPNFXSQZUPQ-UHFFFAOYSA-N 0.000 description 1
VXUXMYSLPRSGCO-UHFFFAOYSA-N 2-(quinolin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C3=CC=CC=C3N=CC=2)=C1 VXUXMYSLPRSGCO-UHFFFAOYSA-N 0.000 description 1
DTBSUGRDDMJPFG-UHFFFAOYSA-N 2-(quinolin-5-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C3=CC=CN=C3C=CC=2)=C1 DTBSUGRDDMJPFG-UHFFFAOYSA-N 0.000 description 1
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
YHDZRNDQGXCQPC-UHFFFAOYSA-N 2-[(1-methyl-6-oxopyridin-3-yl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(=O)N(C)C=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 YHDZRNDQGXCQPC-UHFFFAOYSA-N 0.000 description 1
MNKGORCKZLHKOM-UHFFFAOYSA-N 2-[(1-oxidopyridin-1-ium-4-yl)methylamino]-n-[4-propyl-3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(CCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=[N+]([O-])C=C1 MNKGORCKZLHKOM-UHFFFAOYSA-N 0.000 description 1
WXIRDFFVKYJFNF-UHFFFAOYSA-N 2-[(3-hydroxyphenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound OC1=CC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 WXIRDFFVKYJFNF-UHFFFAOYSA-N 0.000 description 1
SROGXBDSTRHYPA-UHFFFAOYSA-N 2-[(6-methoxypyridin-3-yl)methylamino]-n-[4-propyl-3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(CCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(OC)N=C1 SROGXBDSTRHYPA-UHFFFAOYSA-N 0.000 description 1
NINCSGUFEFCKJV-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridin-3-yl)methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC2=CNC(=O)C=C2)=C1 NINCSGUFEFCKJV-UHFFFAOYSA-N 0.000 description 1
GZOMFQTVBZEVRC-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridin-3-yl)methylamino]-n-[4-prop-1-ynyl-3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(C#CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CNC(=O)C=C1 GZOMFQTVBZEVRC-UHFFFAOYSA-N 0.000 description 1
BDWFYCHKKLPRBV-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridin-3-yl)methylamino]-n-[4-propyl-3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(CCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CNC(=O)C=C1 BDWFYCHKKLPRBV-UHFFFAOYSA-N 0.000 description 1
SIXBYWLNDNISBA-UHFFFAOYSA-N 2-chloro-n-(4-chlorophenyl)-6-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=C(Cl)C=CC=C1NCC1=CC=NC=C1 SIXBYWLNDNISBA-UHFFFAOYSA-N 0.000 description 1
XLCHGJROVMIGEQ-UHFFFAOYSA-N 2-methyl-n-(4-methylphenyl)-6-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=C(C)C=CC=C1NCC1=CC=NC=C1 XLCHGJROVMIGEQ-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
CARBQIOXWBDDLK-UHFFFAOYSA-N 3-(methylamino)-2-(pyridin-4-ylmethyl)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C=1C=NC=CC=1CC=1C(NC)=CC=CC=1C(=O)NC1=CC=CC(C(F)(F)F)=C1 CARBQIOXWBDDLK-UHFFFAOYSA-N 0.000 description 1
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
XCIAQBNRTOSKGE-UHFFFAOYSA-N 4-chloro-n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=C(Cl)C=C1NCC1=CC=NC=C1 XCIAQBNRTOSKGE-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
JESYNXSSGGGWHY-UHFFFAOYSA-N 5-chloro-n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC(Cl)=CC=C1NCC1=CC=NC=C1 JESYNXSSGGGWHY-UHFFFAOYSA-N 0.000 description 1
KTTKWRSNHRKIEM-UHFFFAOYSA-N 5-methoxy-2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1NC(=O)C1=CC(OC)=CC=C1NCC1=CC=NC=C1 KTTKWRSNHRKIEM-UHFFFAOYSA-N 0.000 description 1
AECDBHGVIIRMOI-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CC(CN3CCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 AECDBHGVIIRMOI-UHFFFAOYSA-N 0.000 description 1
PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
108090000644 Angiozyme Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
FJWVOOJOHKFDGO-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C=1C=C(C=CC=1)C1=C(C(=O)N)C=CC=C1 Chemical compound C(C1=CC=CC=C1)(=O)C=1C=C(C=CC=1)C1=C(C(=O)N)C=CC=C1 FJWVOOJOHKFDGO-UHFFFAOYSA-N 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
FVEVRFMDPKOBSU-HDICACEKSA-N C1C[C@H](C(C)(C)C)CC[C@@H]1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound C1C[C@H](C(C)(C)C)CC[C@@H]1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FVEVRFMDPKOBSU-HDICACEKSA-N 0.000 description 1
UBBPGGOGAXXNSD-CALCHBBNSA-N C1C[C@H](C(C)(C)C)CC[C@@H]1NC(=O)C1=CC=CN=C1NCC1=CNC(=O)C=C1 Chemical compound C1C[C@H](C(C)(C)C)CC[C@@H]1NC(=O)C1=CC=CN=C1NCC1=CNC(=O)C=C1 UBBPGGOGAXXNSD-CALCHBBNSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
229940126049 IMC-1 Drugs 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
241000764238 Isis Species 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000003666 Placenta Growth Factor Human genes 0.000 description 1
108010082093 Placenta Growth Factor Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
108050001286 Somatostatin Receptor Proteins 0.000 description 1
102000011096 Somatostatin receptor Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
229940110331 bextra Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
229960005539 bryostatin 1 Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940047495 celebrex Drugs 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
LSFLAQVDISHMNB-AFARHQOCSA-N chembl399021 Chemical compound C1=2C(N)=NC=NC=2N([C@@H]2C[C@@H](CN3CCCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 LSFLAQVDISHMNB-AFARHQOCSA-N 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
229960003654 desoxycortone Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
WEHDKOIKSRMLEK-UHFFFAOYSA-N ethanesulfonic acid;2-hydroxyethanesulfonic acid Chemical compound CCS(O)(=O)=O.OCCS(O)(=O)=O WEHDKOIKSRMLEK-UHFFFAOYSA-N 0.000 description 1
FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
229960004945 etoricoxib Drugs 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
150000002238 fumaric acids Chemical class 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
150000002537 isoquinolines Chemical class 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
229940080268 lotensin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000035168 lymphangiogenesis Effects 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
OSJPJZFGLGZKGT-UHFFFAOYSA-N methyl 2-[3-[[2-(pyridin-4-ylmethylamino)benzoyl]amino]phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 OSJPJZFGLGZKGT-UHFFFAOYSA-N 0.000 description 1
125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
229950010895 midostaurin Drugs 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960005170 moexipril Drugs 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
HFDDMCYJQSACMD-UHFFFAOYSA-N n-(1h-indazol-5-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2NN=CC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HFDDMCYJQSACMD-UHFFFAOYSA-N 0.000 description 1
JGMZJWDJMGZRIN-UHFFFAOYSA-N n-(2-methylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound CC1=CC=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 JGMZJWDJMGZRIN-UHFFFAOYSA-N 0.000 description 1
VGFZTILOARHEBE-UHFFFAOYSA-N n-(3-acetamidophenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound CC(=O)NC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 VGFZTILOARHEBE-UHFFFAOYSA-N 0.000 description 1
XUOAHFWPZDKHOZ-UHFFFAOYSA-N n-(3-bromonaphthalen-2-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound BrC1=CC2=CC=CC=C2C=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 XUOAHFWPZDKHOZ-UHFFFAOYSA-N 0.000 description 1
UYQCVZFUMLNJMY-UHFFFAOYSA-N n-(3-bromophenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound BrC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 UYQCVZFUMLNJMY-UHFFFAOYSA-N 0.000 description 1
GVMJDDUKKBWEKI-UHFFFAOYSA-N n-(3-carbamoylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound NC(=O)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 GVMJDDUKKBWEKI-UHFFFAOYSA-N 0.000 description 1
DSSVKXOIKNNJON-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 DSSVKXOIKNNJON-UHFFFAOYSA-N 0.000 description 1
OVMDIFAQBUDXLQ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound ClC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 OVMDIFAQBUDXLQ-UHFFFAOYSA-N 0.000 description 1
BRANEJBIQCMAFA-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C(F)C(C)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 BRANEJBIQCMAFA-UHFFFAOYSA-N 0.000 description 1
CKHZHTUSZIEKAA-UHFFFAOYSA-N n-(3-methylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 CKHZHTUSZIEKAA-UHFFFAOYSA-N 0.000 description 1
XFEQUXYPXZBGCZ-UHFFFAOYSA-N n-(4-chloronaphthalen-1-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C12=CC=CC=C2C(Cl)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 XFEQUXYPXZBGCZ-UHFFFAOYSA-N 0.000 description 1
PMNJFLWFHFBXAV-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(1h-imidazol-2-ylmethylamino)benzamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CC=C1NCC1=NC=CN1 PMNJFLWFHFBXAV-UHFFFAOYSA-N 0.000 description 1
RHUBFQSQWPIKRE-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC2=CC=CC=C12 RHUBFQSQWPIKRE-UHFFFAOYSA-N 0.000 description 1
GGPZCOONYBPZEW-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 GGPZCOONYBPZEW-UHFFFAOYSA-N 0.000 description 1
BXMRYBCMIBDOAI-UHFFFAOYSA-N n-(4-chlorophenyl)-2-methyl-6-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=C(Cl)C=CC=1NC(=O)C=1C(C)=CC=CC=1NCC1=CC=NC=C1 BXMRYBCMIBDOAI-UHFFFAOYSA-N 0.000 description 1
HZLCVWPDLSEITB-UHFFFAOYSA-N n-(4-chlorophenyl)-4,5-dimethyl-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=C(Cl)C=CC=1NC(=O)C=1C=C(C)C(C)=CC=1NCC1=CC=NC=C1 HZLCVWPDLSEITB-UHFFFAOYSA-N 0.000 description 1
RYNWCPLCPVZYNO-UHFFFAOYSA-N n-(4-chlorophenyl)-5-methyl-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=C(Cl)C=CC=1NC(=O)C1=CC(C)=CC=C1NCC1=CC=NC=C1 RYNWCPLCPVZYNO-UHFFFAOYSA-N 0.000 description 1
IVHOTBKUXHFPGN-UHFFFAOYSA-N n-(4-chlorophenyl)-6-(pyridin-4-ylmethylamino)-1,3-benzodioxole-5-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C(C(=C1)NCC=2C=CN=CC=2)=CC2=C1OCO2 IVHOTBKUXHFPGN-UHFFFAOYSA-N 0.000 description 1
UQMAAAURUGSGFU-UHFFFAOYSA-N n-(4-methoxynaphthalen-2-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C2=CC=CC=C2C(OC)=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 UQMAAAURUGSGFU-UHFFFAOYSA-N 0.000 description 1
PGBQLTBGHJJFQA-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 PGBQLTBGHJJFQA-UHFFFAOYSA-N 0.000 description 1
DWINSYOAIHBVOY-UHFFFAOYSA-N n-(4-methylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 DWINSYOAIHBVOY-UHFFFAOYSA-N 0.000 description 1
FCVFLHKZINDTJU-UHFFFAOYSA-N n-(4-pentylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCCCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FCVFLHKZINDTJU-UHFFFAOYSA-N 0.000 description 1
OWSVTXJVKRNRSJ-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=CC=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 OWSVTXJVKRNRSJ-UHFFFAOYSA-N 0.000 description 1
CQWKRTDZKYVAGQ-UHFFFAOYSA-N n-(4-prop-1-ynylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C#CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 CQWKRTDZKYVAGQ-UHFFFAOYSA-N 0.000 description 1
YOOJWMUGDPZTTJ-UHFFFAOYSA-N n-(4-propylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YOOJWMUGDPZTTJ-UHFFFAOYSA-N 0.000 description 1
GZMLTGKXCXTWQI-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 GZMLTGKXCXTWQI-UHFFFAOYSA-N 0.000 description 1
RCGXAILYGYDFNT-UHFFFAOYSA-N n-(8-hydroxynaphthalen-2-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C2C(O)=CC=CC2=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 RCGXAILYGYDFNT-UHFFFAOYSA-N 0.000 description 1
HVOSJPTYYJIOAR-UHFFFAOYSA-N n-[2-fluoro-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HVOSJPTYYJIOAR-UHFFFAOYSA-N 0.000 description 1
WXUJEMFCVOWGJI-UHFFFAOYSA-N n-[2-fluoro-3-(trifluoromethyl)phenyl]-2-[(6-methoxypyridin-3-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC=C1CNC1=NC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1F WXUJEMFCVOWGJI-UHFFFAOYSA-N 0.000 description 1
QNJCKBPELFXYMN-UHFFFAOYSA-N n-[2-methyl-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QNJCKBPELFXYMN-UHFFFAOYSA-N 0.000 description 1
FMGUROJQQMGCFQ-UHFFFAOYSA-N n-[2-methyl-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FMGUROJQQMGCFQ-UHFFFAOYSA-N 0.000 description 1
DMAQJZSSUGMOTF-UHFFFAOYSA-N n-[3,4-bis(trifluoromethyl)phenyl]-2-[(1-methyl-6-oxopyridin-3-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(=O)N(C)C=C1CNC1=NC=CC=C1C(=O)NC1=CC=C(C(F)(F)F)C(C(F)(F)F)=C1 DMAQJZSSUGMOTF-UHFFFAOYSA-N 0.000 description 1
KETBEBUIIHDMCX-UHFFFAOYSA-N n-[3,4-bis(trifluoromethyl)phenyl]-2-[(6-oxo-1h-pyridin-3-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CNC(=O)C=C1 KETBEBUIIHDMCX-UHFFFAOYSA-N 0.000 description 1
JOGLPJZUGCTJCW-UHFFFAOYSA-N n-[3-chloro-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound FC(F)(F)C1=CC(Cl)=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 JOGLPJZUGCTJCW-UHFFFAOYSA-N 0.000 description 1
NPLKLHOIHHQADR-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound FC(F)(F)C1=CC(F)=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 NPLKLHOIHHQADR-UHFFFAOYSA-N 0.000 description 1
COGCKRLDYTZKNF-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 COGCKRLDYTZKNF-UHFFFAOYSA-N 0.000 description 1
UQKMNJCWRXFQEZ-UHFFFAOYSA-N n-[3-methoxy-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound FC(F)(F)C1=CC(OC)=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 UQKMNJCWRXFQEZ-UHFFFAOYSA-N 0.000 description 1
VFGCRQJWYNDWDF-UHFFFAOYSA-N n-[4-(propan-2-ylcarbamoyl)phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 VFGCRQJWYNDWDF-UHFFFAOYSA-N 0.000 description 1
OBOBQYCSGNROCS-UHFFFAOYSA-N n-[4-bromo-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Br)C(C(F)(F)F)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 OBOBQYCSGNROCS-UHFFFAOYSA-N 0.000 description 1
NRDUIAQHBWVVNX-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 NRDUIAQHBWVVNX-UHFFFAOYSA-N 0.000 description 1
HACFEPKYXGTAHA-UHFFFAOYSA-N n-[4-prop-1-ynyl-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(C#CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HACFEPKYXGTAHA-UHFFFAOYSA-N 0.000 description 1
KAXWYUCTTYGRDT-UHFFFAOYSA-N n-[4-propyl-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(CCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KAXWYUCTTYGRDT-UHFFFAOYSA-N 0.000 description 1
MCUIEWFNWZMXBM-UHFFFAOYSA-N n-isoquinolin-3-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C2=CC=CC=C2C=NC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 MCUIEWFNWZMXBM-UHFFFAOYSA-N 0.000 description 1
NINPISWMZONASJ-UHFFFAOYSA-N n-naphthalen-1-yl-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 NINPISWMZONASJ-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
LHMQYJIWUHCFSG-UHFFFAOYSA-N n-phenyl-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=CC=C(NCC=2C=CN=CC=2)C=1C(=O)NC1=CC=CC=C1 LHMQYJIWUHCFSG-UHFFFAOYSA-N 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
229950010632 perifosine Drugs 0.000 description 1
125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
229940099538 rapamune Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
229950008902 safingol Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
229960003787 sorafenib Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
229960002004 valdecoxib Drugs 0.000 description 1
LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229960003895 verteporfin Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229940061392 visudyne Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
229950009819 zotarolimus Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Surgery (AREA)
Epidemiology (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

CA002539230A 2003-09-23 2004-09-23 Combinaisons d'un inhibiteur du recepteur du vegf et d'autres agents therapeutiques Abandoned CA2539230A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50525503P	2003-09-23	2003-09-23
US60/505255		2003-09-23
PCT/EP2004/010701 WO2005027973A2 (fr)	2003-09-23	2004-09-23	Combinaisons d'un inhibiteur du recepteur du vegf et d'autres agents therapeutiques

Publications (1)

Publication Number	Publication Date
CA2539230A1 true CA2539230A1 (fr)	2005-03-31

Family

ID=34375570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002539230A Abandoned CA2539230A1 (fr)	2003-09-23	2004-09-23	Combinaisons d'un inhibiteur du recepteur du vegf et d'autres agents therapeutiques

Country Status (8)

Country	Link
EP (1)	EP1667721A2 (fr)
JP (1)	JP2007505939A (fr)
CN (1)	CN1856326A (fr)
AU (1)	AU2004273619A1 (fr)
BR (1)	BRPI0414604A (fr)
CA (1)	CA2539230A1 (fr)
MX (1)	MXPA06003164A (fr)
WO (1)	WO2005027973A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399480B2 (en)	1997-09-26	2008-07-15	Abbott Laboratories	Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en)	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
KR20070004795A (ko) *	2004-04-02	2007-01-09	노파르티스 아게	Ｖｅｇｆ 수용체 타이로신 키나제 억제제 코팅된 스텐트
MX2007011866A (es) *	2005-02-25	2007-10-10	Novartis Ag	Combinacion farmaceutica de inhibidores de bcr-abl y raf.
WO2007087575A2 (fr) *	2006-01-24	2007-08-02	University Of Chicago	Compositions et procedes destines au traitement de l'hypertension pulmonaire
CN100502945C (zh) *	2006-03-31	2009-06-24	成都康弘生物科技有限公司	Vegf受体融合蛋白在治疗眼睛疾病中的应用
EP2012794B1 (fr) *	2006-04-13	2014-09-17	The Trustees of Columbia University in the City of New York	Compositions et dispositifs intraluminaux permettant d'inhiber la stenose vasculaire
EP2012826B1 (fr) *	2006-05-04	2016-04-13	Fovea Pharmaceuticals	Combinaison comprenant un inhibiteur de vegf et une protease a serine pour le traitement des maladies néovasculaires
US20070275029A1 (en) *	2006-05-26	2007-11-29	Ico Therapeutics Inc.	Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
US20100256136A1 (en) *	2006-07-10	2010-10-07	Pandey Ravindra K	Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor
US8685995B2 (en)	2008-03-21	2014-04-01	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
EP2156834A1 (fr) *	2008-08-08	2010-02-24	S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A.	Compositions pharmaceutiques ophtalmiques comprenant du Sorafenib pour le traitement de pathologies néoangiogéniques de l'ýil
US8962561B2 (en) *	2009-11-12	2015-02-24	Ramot At Tel-Aviv University Ltd.	Compositions comprising PEDF and uses of same in the treatment and prevention of ovary-related syndromes
DK2524693T3 (da)	2010-01-14	2014-08-25	Sanwa Kagaku Kenkyusho Co	Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet
WO2012105610A1 (fr)	2011-02-02	2012-08-09	公立大学法人名古屋市立大学	Agent médicinal pour la prévention ou le traitement de maladies associées à une néovascularisation intraoculaire et/ou une hyperperméabilité vasculaire intraoculaire
CN106581666A (zh) *	2016-11-23	2017-04-26	新乡医学院	Pedf在制备治疗糖尿病骨组织并发症药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU729869B2 (en) *	1997-01-17	2001-02-15	Merck & Co., Inc.	Integrin antagonists
GB0001930D0 (en) *	2000-01-27	2000-03-22	Novartis Ag	Organic compounds
US6313138B1 (en) *	2000-02-25	2001-11-06	Merck & Co., Inc.	Tyrosine kinase inhibitors
US7105682B2 (en) *	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
US6995162B2 (en) *	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
WO2002102783A1 (fr) *	2001-06-19	2002-12-27	Merck & Co., Inc.	Inhibiteurs de la tyrosine kinase
WO2003015778A1 (fr) *	2001-08-17	2003-02-27	Merck & Co., Inc.	Inhibiteurs de tyrosine kinase
US20050043409A1 (en) *	2001-10-25	2005-02-24	Chen Ying-Nan Pan	Combinations comprising a selective cyclooxygenase-2 inhibitor

2004
- 2004-09-23 CA CA002539230A patent/CA2539230A1/fr not_active Abandoned
- 2004-09-23 CN CNA2004800275352A patent/CN1856326A/zh active Pending
- 2004-09-23 AU AU2004273619A patent/AU2004273619A1/en not_active Abandoned
- 2004-09-23 MX MXPA06003164A patent/MXPA06003164A/es not_active Application Discontinuation
- 2004-09-23 EP EP04765555A patent/EP1667721A2/fr not_active Withdrawn
- 2004-09-23 JP JP2006527355A patent/JP2007505939A/ja active Pending
- 2004-09-23 WO PCT/EP2004/010701 patent/WO2005027973A2/fr not_active Ceased
- 2004-09-23 BR BRPI0414604-2A patent/BRPI0414604A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA06003164A (es)	2006-06-05
WO2005027973A3 (fr)	2005-09-09
JP2007505939A (ja)	2007-03-15
WO2005027973A2 (fr)	2005-03-31
EP1667721A2 (fr)	2006-06-14
CN1856326A (zh)	2006-11-01
BRPI0414604A (pt)	2006-11-07
AU2004273619A1 (en)	2005-03-31

Publication	Publication Date	Title
CA2539230A1 (fr)	2005-03-31	Combinaisons d'un inhibiteur du recepteur du vegf et d'autres agents therapeutiques
AU2004273615B2 (en)	2009-01-15	Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
JP5212849B2 (ja)	2013-06-19	眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2004513964A (ja)	2004-05-13	Ｖｅｇｆ活性低減剤およびｅｇｆ活性低減剤を含む組合せ剤
AU2003228991B8 (en)	2009-07-02	Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
JP2011528015A (ja)	2011-11-10	線維症を治療するためのピリミジルアミノベンズアミド誘導体の使用
CN103391782A (zh)	2013-11-13	用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物
JP4942297B2 (ja)	2012-05-30	肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
JP2008517974A (ja)	2008-05-29	抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
EP1105136A2 (fr)	2001-06-13	Methode de traitement de maladies oculaires neovasculaires
JP2004534760A (ja)	2004-11-18	腎線維症の治療
EP4240354A1 (fr)	2023-09-13	Inhibiteur de raf pour traiter le gliome de bas grade
CN110604734A (zh)	2019-12-24	同时减少出血和微血管阻塞风险的药物
KR20210058586A (ko)	2021-05-24	실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물
WO2007020509A1 (fr)	2007-02-22	Combinaison d'agents de transfert du méthylol et de protéines ou de peptides inhibiteurs de tumeurs, et emploi de ladite combinaison dans le traitement d'un cancer ou d'une croissance tumorale
CA2490130A1 (fr)	2004-01-08	Combinaison contenant un compose vasculostatique et un agent d'alkylation destinee au traitement d'une tumeur
AU2012331125A1 (en)	2014-05-22	2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases
EP1581228A1 (fr)	2005-10-05	Traitement de la maladie de von hippel lindau
JP2011510994A (ja)	2011-04-07	末梢動脈疾患の治療のためのｐｄｅ３阻害剤の増減投与方法

Legal Events

Date	Code	Title	Description
2008-09-23	FZDE	Dead